Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (3 quarters reported)
$87.5M in Q4 2025 → $136M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Acadia Pharmaceuticals Inc | 7.6% | Added 233% | 410,000 | $10.4M |
| Xeris Biopharma Holdings Inc | 7.2% | Added 20% | 1,230,000 | $9.74M |
| Biomarin Pharmaceutical Inc | 6.0% | Added 75% | 143,500 | $8.21M |
| PP Praxis Precision Medicines I | 5.5% | Unchanged | 22,550 | $7.55M |
| UP Ultragenyx Pharmaceutical In | 5.0% | Added 18% | 205,000 | $6.84M |
| Agios Pharmaceuticals Inc | 4.5% | New | 164,000 | $6.09M |
| Insmed Inc | 4.0% | New | 51,250 | $5.46M |
| CP Crinetics Pharmaceuticals In | 3.9% | New | 143,500 | $5.37M |
| Zentalis Pharmaceuticals Inc | 3.7% | Trimmed 17% | 1,025,000 | $4.97M |
| Vaxcyte Inc | 3.5% | Added 43% | 82,000 | $4.77M |
| Annexon Inc | 3.4% | Added 371% | 820,000 | $4.68M |
| Travere Therapeutics Inc | 3.4% | Trimmed 26% | 82,000 | $4.66M |
| TP Tonix Pharmaceuticals Hldg C | 3.2% | New | 338,250 | $4.32M |
| Bridgebio Pharma Inc | 3.1% | New | 57,400 | $4.28M |
| Axsome Therapeutics Inc. | 2.9% | Trimmed 60% | 16,400 | $4.01M |
| Contineum Therapeutics Inc | 2.5% | Added 44% | 205,000 | $3.36M |
| Lexicon Pharmaceuticals Inc | 2.2% | Added 41% | 1,271,000 | $3.05M |
| Kura Oncology Inc | 2.2% | New | 276,750 | $3.04M |
| DT Dbv Technologies S A | 2.2% | Added 80% | 184,500 | $3.03M |
| Genmab A/s | 2.1% | Added 25% | 102,500 | $2.82M |
| Cytokinetics Inc | 2.1% | New | 32,800 | $2.79M |
| Mineralys Therapeutics Inc | 2.0% | Added 25% | 102,500 | $2.77M |
| Silence Therapeutics PLC | 1.8% | Trimmed 61% | 55,350 | $2.43M |
| Nuvation Bio Inc | 1.5% | New | 369,000 | $2.1M |
| Wave Life Sciences Ltd | 1.4% | New | 328,000 | $1.91M |
| Nektar Therapeutics | 1.4% | New | 26,650 | $1.86M |
| SR Scholar Rock Hldg Corp | 1.2% | Trimmed 46% | 30,750 | $1.69M |
| Enliven Therapeutics Inc | 1.2% | New | 32,800 | $1.66M |
| Alnylam Pharmaceuticals Inc | 1.1% | Unchanged | 5,125 | $1.54M |
| Beam Therapeutics Inc | 1.0% | Trimmed 29% | 41,000 | $1.41M |
| Sionna Therapeutics Inc | 1.0% | Added 150% | 123,000 | $1.35M |
| Oric Pharmaceuticals Inc | 1.0% | Added 20% | 123,000 | $1.33M |
| NP Newamsterdam Pharma Company | 0.9% | Unchanged | 36,900 | $1.25M |
| Vertex Pharmaceuticals Inc | 0.9% | New | 2,460 | $1.22M |
| Ars Pharmaceuticals Inc | 0.8% | New | 143,490 | $1.15M |
| Monopar Therapeutics Inc | 0.8% | New | 12,300 | $1.14M |
| Erasca Inc | 0.6% | New | 41,000 | $751K |
| Vera Therapeutics Inc | 0.3% | Trimmed 88% | 10,250 | $440K |
| Immatics N.v | 0.2% | Trimmed 80% | 30,750 | $311K |
| Mereo Biopharma Group PLC | 0.2% | New | 768,750 | $244K |
| Gossamer Bio Inc | 0.1% | Unchanged | 820,000 | $135K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 2 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Acadia Pharmaceuticals Inc | Added | +287,000 | +$7.26M | 7.6% |
| PP Praxis Precision Medicines I | Exited | −20,500 | −$6.6M | — |
| Agios Pharmaceuticals Inc | New | +164,000 | +$6.09M | 4.5% |
| Axsome Therapeutics Inc. | Trimmed | −24,600 | −$6.02M | 2.9% |
| Kalvista Pharmaceuticals Inc | Exited | −276,750 | −$5.57M | — |
| Insmed Inc | New | +51,250 | +$5.46M | 4.0% |
| CP Crinetics Pharmaceuticals In | New | +143,500 | +$5.37M | 3.9% |
| AT Amicus Therapeutic | Exited | −369,000 | −$5.34M | — |
| Verastem Inc | Exited | −820,000 | −$4.35M | — |
| TP Tonix Pharmaceuticals Hldg C | New | +338,250 | +$4.32M | 3.2% |
Showing the 10 largest of 49 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Axsome Therapeutics Inc. | New | +41,000 | +$6.93M | 6.6% |
| PP Praxis Precision Medicines I | New | +20,500 | +$6.6M | 6.3% |
| PP Praxis Precision Medicines I | Trimmed | −17,450 | −$5.62M | 6.9% |
| Kalvista Pharmaceuticals Inc | New | +276,750 | +$5.57M | 5.3% |
| Nuvation Bio Inc | Exited | −400,000 | −$3.58M | — |
| AP Arrowhead Pharmaceuticals In | New | +55,350 | +$3.47M | 3.3% |
| Vera Therapeutics Inc | New | +82,000 | +$3.3M | 3.1% |
| Travere Therapeutics Inc | New | +110,700 | +$3.29M | 3.1% |
| Moonlake Immunotherapeutics | New | +174,250 | +$3.25M | 3.1% |
| Annexon Inc | Trimmed | −575,750 | −$3.19M | 0.9% |
Showing the 10 largest of 56 changes.
Loading...
